The following two articles were written live from the American Association of Clinical Endocrinologists (AACE) 2017 Annual Meeting in Austin, TX. MPR will be reporting news on the latest findings from leading experts in endocrinology.
The first article covers how a vitamin D deficiency combined with autoimmune subclinical hypothyroidism (SCH) can create higher TSH levels with more symptoms while replacing vitamin D has a significant impact on improving subclinical hypothyroidism.
To date, there have been no studies assessing the outcome of vitamin D replacement on SCH. To test this, they performed an observational, prospective study in Saudi patients with SCH and vitamin D deficiency. After 3 months of treatment with vitamin D, the researchers found a significant increase in serum vitamin D.
You can read the full report here:
Efficacy and compliance to weekly levothyroxine therapy were also studied at the annual meeting in Austin, TX. The weekly levothyroxine therapy was shown to be safe and effective and the findings support its use in newly diagnosed patients with hypothyroidism. For patients who are non-compliant to a rigorous treatment regimen, “it is a valid therapeutic option and can also be considered as a first-line therapy in young and middle-aged working adults facing impaired absorption due to early breakfast,” added Dr. Wasoori.
I find it quite impressive that doctors would be concerned about absorption in working adults. It would be awesome if you could take a dose once a week and have your symptoms controlled.
Here is that report: